Abstracts tagged "Bone density"

Abstract Number: 1328 • ACR Convergence 2022
CT Evaluation of Bone Fragility 2 Years After Bariatric Surgery in Patients with Obesity: An Observational Study
Marine FAUNY¹, Marion Halin², Edem Allado², Didier Quilliot², Laurent Brunaud², Eliane Albuisson², Isabelle Chary-Valckenaere² and Damien Loeuille², ¹Nancy University Hospital, Toul, France, ²Nancy University Hospital, Vandoeuvre, France
Background/Purpose: The objectives were to evaluate bone fragility on computed tomography (CT) in patients with obesity before and 2 years after bariatric surgery and to…
Abstract Number: 1329 • ACR Convergence 2022
Prevalence of Bone Fragility on DXA and CT in Patients with Obesity
Marion Halin¹, Edem Allado¹, Didier Quilliot¹, Eliane Albuisson¹, Isabelle Chary-Valckenaere¹, Damien Loeuille¹, Laurent Brunaud¹ and Marine FAUNY², ¹Nancy University Hospital, Vandoeuvre, France, ²Nancy University Hospital, Toul, France
Background/Purpose: Primary objective was to evaluate bone fragility prevalence on dual X-ray absorptiometry (DXA) and on computed tomography (CT), in patients with severe obesity. Secondary…
Abstract Number: 1331 • ACR Convergence 2022
Risk Factors for Osteoporotic Fracture in Women with Established Long-Term Rheumatoid Arthritis
Felipe Freire da Silva¹, Gisela Machado², ana Medeiros³, Karina Bonfiglioli⁴, Andrea Shimabuco², Liliam Takayama⁵, Rosa Pereira⁶ and Diogo Domiciano⁷, ¹FMUSP, Salvador, Brazil, ²FMUSP, São Paulo, Brazil, ³Faculdade de Medicina da Universidade de São Paulo, São Jose Dos Campos, Brazil, ⁴Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁵University of São Paulo, São Paulo, Brazil, ⁶Bone Metabolism Laboratory, Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁷Hospital das Clinicas, Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Low bone mineral density (BMD) is a predictor of osteoporotic fracture. However, individuals with Rheumatoid Arthritis (RA) who sustain "osteoporosis-related" fractures frequently have normal…
Abstract Number: 1503 • ACR Convergence 2022
Is Inflammation-driven Bone Loss Associated with Two-year Bone Formation at the Same Vertebra in Axial Spondyloarthritis? – a Multilevel MRI and Low Dose CT Analysis from the Sensitive Imaging of Axial Spondyloarthritis (SIAS) Cohort
Mary Lucy Marques¹, Nuno Pereira da Silva², Désirée van der Heijde³, Rosalinde Stal⁴, Xenofon Baraliakos⁵, Juergen Braun⁶, Monique Reijnierse⁴, Caroline Bastiaenen⁷, Sofia Ramiro⁴ and floris van Gaalen⁴, ¹Leiden University Medical Center, Coimbra, Portugal, ²Radiology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, ³Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ⁶Rheumazentrum Ruhrgebiet, Herne, Germany, ⁷Department of Epidemiology, Maastricht University, Maastricht, Netherlands
Background/Purpose: In radiographic axial spondyloarthritis (r-axSpA), inflammation-driven trabecular bone loss is hypothesised to trigger bone repair at an anatomically distinct site of the same vertebra…
Abstract Number: 1894 • ACR Convergence 2022
A Phase 2, 104-Week Study of Repeat Lorecivivint Injections Evaluating Safety, Efficacy, and Bone Health Utilizing Quantitative Computed Tomography (qCT) in Knee Osteoarthritis (OA-06)
Yusuf Yazici¹, Christopher Swearingen², Heli Ghandehari³, Jon Britt⁴, ismail simsek⁵, Mark Fineman⁶, Sarah Kennedy², Jeyanesh Tambiah⁷ and Nancy Lane⁸, ¹New York University School of Medicine, La Jolla, CA, ²Biosplice Therapeutics, Inc, San Diego, CA, ³Biosplice Therapeutics, Inc., San Diego, CA, ⁴Biosplice Therapeutics, Inc., Los Angeles, CA, ⁵Alpine Immunesciences, San Diego, CA, ⁶Biosplice Therapeutics, San Diego, CA, ⁷Biosplice Ther Inc., San Diego, CA, ⁸University of California Davis, Hillsborough, CA
Background/Purpose: Knee osteoarthritis (OA) is a common joint disorder associated with pain, disability, and joint damage. There is a large unmet need for safe and…
Abstract Number: 0131 • ACR Convergence 2022
Racial Differences in Bone Health of Sarcoidosis Patients: A Retrospective Study
Emily Peninger¹, Christian Ascoli², Rachel Lane², Subash Kukreja², Robert Baughman³ and Nadera Sweiss², ¹University of Chicago, Chicago, IL, ²University of Illinois at Chicago, Chicago, IL, ³University of Cincinnati, Cincinnati, OH
Background/Purpose: Bone health in sarcoidosis is a complex topic, though data regarding racial differences in this population is lacking. Our study sought to identify racial…
Abstract Number: 1995 • ACR Convergence 2022
Baricitinib Improves Bone Biomechanical Properties in Rheumatoid Arthritis (RA) – Results of a Prospective Interventional Study
Stephan Kemenes¹, Koray Tascilar², David Simon¹, Sara Bayat³, Gerhard Kroenke², Larissa Valor Mendez², Fabian Hartmann⁴, Louis Schuster⁴, Anna-Maria Liphardt¹, Georg Schett⁵ and Arnd Kleyer², ¹Department of Internal Medicine 3, Rheumatoloy and Immunology, University Hospital Erlangen, Erlangen, Germany, ²Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-UniversityErlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ³University Hospital Erlangen; Department of Internal Medicine 3 - Rheumatology and Immunology, Erlangen, Germany, ⁴University Hospital Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology, Erlangen, Germany, ⁵Universitätsklinikum Erlangen, Erlangen, Germany
Background/Purpose: Deterioration of peripheral bone mass and bone biomechanics are well-known consequences of Rheumatoid Arthritis (RA)[1]. CCP-AB pos. RA, in particular, leads to a significant…
Abstract Number: 0430 • ACR Convergence 2022
The Course of Bone Mineral Density During 8 Years of Treatment with TNF-α Inhibitors in Patients with Ankylosing Spondylitis
Mark Siderius¹, Anneke Spoorenberg², Freke Wink³ and Suzanne Arends², ¹University Medical Centre Groningen, Groningen, Netherlands, ²University Medical Center Groningen, Groningen, Netherlands, ³Medical Center Leeuwarden, Leeuwarden, Netherlands
Background/Purpose: Bone loss reflected by lower bone mineral density (BMD) compared to age and gender matched healthy controls is a common feature of ankylosing spondylitis…
Abstract Number: 0445 • ACR Convergence 2021
Safety and Efficacy of Denosumab vs Risedronate in Patients with Glucocorticoid-Induced Osteoporosis and Rheumatoid Arthritis
Jonathan Adachi¹, Arkadi Chines², Shuang Huang², Kenneth Saag³, Willem Lems⁴ and Piet Geusens⁵, ¹McMaster University/St. Joseph's Healthcare, Hamilton, ON, Canada, ²Amgen Inc., Thousand Oaks, CA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴VUmc, Amsterdam, Netherlands, ⁵Maastricht University, Genk, Belgium
Background/Purpose: Denosumab (DMAb) is approved for the treatment of glucocorticoid (GC)–induced osteoporosis (GiOP). In a phase 3, international, active-controlled, double-blind, double-dummy study, treatment with DMAb…
Abstract Number: 1017 • ACR Convergence 2021
Osteoclast-Specific Transmembrane Protein (OC-STAMP) Regulates Osteoclastogenesis and Inhibits Inflammation in an Acute Arthritis Model
Maria de la Luz Garcia-Hernandez¹, Javier Rangel-Moreno¹, Ananta Paine¹, Jacob R. Jones¹, Marc Nuzzo¹, Lidsay N. Schnur² and Christopher Ritchlin¹, ¹Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, ²University of Rochester, Rochester, NY
Background/Purpose: Dendritic Cell (DC)-Specific Transmembrane Protein (STAMP) expressed by osteoclast precursors is required for cell-cell fusion in the formation of the osteoclast (OC) polykaryon. Genetic…
Abstract Number: 1146 • ACR Convergence 2021
Study of Vertebral and Femur Fracture Prevalence and Scanographic Bone Attenuation Coefficient of the First Lumbar Vertebra in an Academic Hospital Setting
Zareen Vaghaiwalla¹, Paul Wasserman¹ and Gurjit Kaeley², ¹University of Florida College of Medicine Jacksonville, Jacksonville, FL, ²University of Florida, Jacksonville, FL
Background/Purpose: Patients with osteoporosis are prone to suffer fragility fractures leading to an increased risk of future fractures. Detection of osteoporosis has been led by…
Abstract Number: 1147 • ACR Convergence 2021
Therapeutic Inertia and Low Patient Compliance: Major Contributors to Low Treatment Rates in Patients with Osteoporosis with Clinical Vertebral Compression Fractures
Shiva Malaty, Paramvir Sidhu, Rustan Sharer and Soo Yeon Kim, HonorHealth Internal Medicine Residency, Scottsdale, AZ
Background/Purpose: Treatment rates with pharmacologic therapy after osteoporotic vertebral fracture are very low in the United States. Underlying causes of these low treatment rates are…
Abstract Number: 1148 • ACR Convergence 2021
Prevalence and Risk Factors of Insufficiency Fractures of the Foot and Ankle Joint in Rheumatic and Musculoskeletal Diseases
Bjoern Buehring¹, Nadine Al-Azem¹, Ioana Andreica¹, David Kiefer², Uta Kiltz¹, Styliani Tsiami¹, Xenofon Baraliakos¹ and Juergen Braun¹, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Essen, Germany
Background/Purpose: Unlike fragility fractures, high-trauma and insufficiency fractures (IF) are not classically considered osteoporotic fractures. Patients with rheumatic and musculoskeletal diseases (RMD), especially those with…
Abstract Number: 1265 • ACR Convergence 2021
Paradoxical Effect of Vitamin D on Bone Mineral Density in SLE
Michelle Petri¹, Jessica Li² and Daniel Goldman¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD
Background/Purpose: Osteoporosis with fractures is consistently one of the top three items in the SLICC/ACR Damage Index in cohort studies internationally. As vitamin D insufficiency…
Abstract Number: 1859 • ACR Convergence 2021
Bone Mineral Density in Patients Diagnosed with Giant Cell Arteritis Taking Glucocorticoids: A Case-control Study
Adam Geressu¹ and Marwan Bukhari², ¹Royal Lancaster Infirmary, Lancaster, United Kingdom, ²British Society for Rheumatology, London, United Kingdom
Background/Purpose: The standard treatment for Giant Cell Arteritis (GCA) is high dose glucocorticoid (GC). It is unknown whether steroids are more detrimental to the spine…

« Previous Page
1
…
4
5
6
7
8
…
16
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].